ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 466.48M
Enterprise value 365.92M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.40
Price/book (mrq)6.94
Enterprise value/revenue 1.24
Enterprise value/EBITDA -2.32

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 3-23.15%
S&P500 52-week change 32.72%
52-week high 321.86
52-week low 38.82
50-day moving average 314.72
200-day moving average 315.76

Share statistics

Avg vol (3-month) 31.16M
Avg vol (10-day) 32.38M
Shares outstanding 541.69M
Implied shares outstanding 6N/A
Float 836.56M
% held by insiders 13.20%
% held by institutions 179.59%
Shares short (14 May 2023) 43.2M
Short ratio (14 May 2023) 44.36
Short % of float (14 May 2023) 47.98%
Short % of shares outstanding (14 May 2023) 47.68%
Shares short (prior month 13 Apr 2023) 43.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 70.27%
Operating margin (ttm)-24.93%

Management effectiveness

Return on assets (ttm)-9.11%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)294.52M
Revenue per share (ttm)8.00
Quarterly revenue growth (yoy)14.90%
Gross profit (ttm)284.73M
EBITDA -73.08M
Net income avi to common (ttm)-173.3M
Diluted EPS (ttm)-5.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)433.6M
Total cash per share (mrq)10.4
Total debt (mrq)333.04M
Total debt/equity (mrq)495.71
Current ratio (mrq)2.37
Book value per share (mrq)1.61

Cash flow statement

Operating cash flow (ttm)-58.25M
Levered free cash flow (ttm)-59.68M